Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | CNR2 | P34972 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17029163 | 0.89 | HTT (0.63) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707656 | 0.87 | MAPT (0.65) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707661 | 0.83 | MAPT (0.63) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707622 | 0.82 | MAPT (0.68) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707655 | 0.81 | MAPT (0.60) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL17230444 | 0.81 | MAPT (0.60) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707662 | 0.81 | MAPT (0.60) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707797 | 0.80 | LMNA (0.66) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707663 | 0.80 | MAPT (0.68) | MAPTCNR2TRPV1MEN1KMT2A | |
| SCHEMBL16707666 | 0.80 | MAPT (0.71) | MAPTCNR2TRPV1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068774-B1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2019-12-25 | — | — | EP | disclosed |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9758489-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758489-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115113-B2 | Azepane derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC., | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315159-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | MAPT 4757/4885CNR2 2306/4885TRPV1 4756/4885 |
| US-10364228-B2 | Azepane derivatives and methods of treating hepatitis B infections | HAVCR2, HDGF, AZI2 | MAPT 4757/4885CNR2 2306/4885TRPV1 4756/4885 |
| US-20180044300-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | MAPT 4757/4885CNR2 2306/4885TRPV1 4756/4885 |
| US-20150132258-A1 | AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, HDGF, AZI2 | MAPT 4757/4885CNR2 2306/4885TRPV1 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.